Federated Hermes Inc. Sells 83,482 Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Federated Hermes Inc. decreased its holdings in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 9.3% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 818,027 shares of the biopharmaceutical company’s stock after selling 83,482 shares during the period. Federated Hermes Inc. owned about 1.42% of Vanda Pharmaceuticals worth $3,452,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. CWM LLC increased its holdings in shares of Vanda Pharmaceuticals by 61.1% during the 3rd quarter. CWM LLC now owns 7,205 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 2,732 shares during the last quarter. Barclays PLC boosted its position in Vanda Pharmaceuticals by 2.6% during the third quarter. Barclays PLC now owns 128,330 shares of the biopharmaceutical company’s stock worth $554,000 after purchasing an additional 3,265 shares during the period. Swiss National Bank increased its holdings in shares of Vanda Pharmaceuticals by 3.4% in the third quarter. Swiss National Bank now owns 126,300 shares of the biopharmaceutical company’s stock valued at $546,000 after purchasing an additional 4,100 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Vanda Pharmaceuticals by 352.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,658 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 5,186 shares during the period. Finally, New York State Common Retirement Fund lifted its stake in shares of Vanda Pharmaceuticals by 57.1% during the 3rd quarter. New York State Common Retirement Fund now owns 17,805 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 6,470 shares during the last quarter. Institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Trading Up 3.1 %

Shares of NASDAQ:VNDA opened at $4.62 on Friday. The stock has a market capitalization of $265.83 million, a PE ratio of 92.42 and a beta of 0.76. The firm has a 50 day moving average of $4.27 and a 200-day moving average of $4.08. Vanda Pharmaceuticals Inc. has a 12 month low of $3.30 and a 12 month high of $7.00.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.05. The business had revenue of $45.27 million during the quarter, compared to the consensus estimate of $37.00 million. Vanda Pharmaceuticals had a net margin of 1.30% and a return on equity of 0.46%. On average, research analysts predict that Vanda Pharmaceuticals Inc. will post -0.06 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on VNDA. StockNews.com lowered shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, April 22nd. TheStreet lowered shares of Vanda Pharmaceuticals from a “c-” rating to a “d” rating in a research report on Thursday, February 8th.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.